Aug 02, 2017 20:30 pm UTC| Business
TORONTO, Aug. 02, 2017 -- Mandalay Resources Corporation (“Mandalay” or “the Company”) (TSX:MND) today announced that its second quarter 2017 financial results will be released after market close on August 10, 2017,...
SAExploration Announces Plans to Reschedule Second Quarter 2017 Earnings Release and Conference Call
Aug 02, 2017 20:30 pm UTC| Business
HOUSTON, Aug. 02, 2017 -- SAExploration Holdings, Inc. (NASDAQ:SAEX) (OTCQB:SXPLW) today announced plans to reschedule the release of its unaudited consolidated financial results for the second quarter and first six...
Neonode to Raise $9.75 Million in Private Placement
Aug 02, 2017 20:30 pm UTC| Business
STOCKHOLM, Sweden, Aug. 02, 2017 -- Neonode Inc. (NASDAQ:NEON), the optical interactive sensing technology company, today announced it has entered into definitive agreements with accredited investors for the private...
Aug 02, 2017 20:30 pm UTC| Business
DENVER, Aug. 02, 2017 -- Resolute Energy Corporation (“Resolute” or the “Company”) (NYSE:REN) announced today that its Board of Directors has approved the appointment of Tod C. Benton and Janet W. Pasque to the Board. ...
Kratos to Present at the Canaccord Genuity Growth Conference
Aug 02, 2017 20:30 pm UTC| Business
SAN DIEGO, Aug. 02, 2017 -- Kratos Defense Security Solutions, Inc. (NASDAQ:KTOS), a leading National Security Solutions provider, today announced that its President CEO, Eric DeMarco, and its Executive VP CFO,...
Globus Medical Announces Acquisition of Robotics Developer KB Medical
Aug 02, 2017 20:30 pm UTC| Business
AUDUBON, Pa., Aug. 02, 2017 -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions manufacturer, today announced that the acquisition of KB Medical, SA, a robotic developer based in Lausanne,...
Mateon Provides Corporate Update and Reports Second Quarter 2017 Financial Results
Aug 02, 2017 20:30 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today...